Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Safety, Tolerability and Efficacy Study of Nalmefene, as Needed Use, in Patients With Alcohol Dependence

NCT00811941 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.

NCT NCT00811941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00811941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Safety, Tolerability and Efficacy Study of Nalmefene, as Needed Use, in Patients With Alcohol Dependence
Lead sponsor
H. Lundbeck A/S
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2009
Completion date
November 30, 2010
Enrollment
665 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

alcohol dependence